Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy

Department of Medicine, University Hospital, London, Ontario, Canada.

Implantable defibrillators reduce the risk of sudden death in patients with malignant ventricular arrhythmias, but significant restriction in quality of life can occur as a result of frequent device activation. To determine if a device that provides both antitachycardia pacing and shock therapy can safely reduce the frequency of shocks after implantation, 46 consecutive patients undergoing initial implantation of a defibrillator were studied. In all patients, the implanted device provided antitachycardia pacing and shock therapy. Detected tachycardia characteristics and the results of therapy were stored in the device's memory. There were 42 men and 4 women, aged 26 to 71 years (mean 58.7 +/- 13.5). Left ventricular ejection fraction ranged from 13% to 67% (mean 32.2 +/- 13.4%) and 31 patients had experienced one or more episodes of cardiac arrest. Induced arrhythmias included sustained monomorphic ventricular tachycardia in 38 patients, nonsustained polymorphic ventricular tachycardia in 2 and ventricular fibrillation in 4. Over a total follow-up period of 255 patient-months (range 1 to 13, mean 6.1), 25 patients experienced spontaneous arrhythmic events. In 22 patients, 909 episodes of tachycardia were treated by antitachycardia pacing, which was successful on 840 occasions (92.4%). Acceleration of ventricular tachycardia by pacing therapy was estimated to have occurred 39 times. Syncope occurred once during pacing-induced acceleration of ventricular tachycardia. Forty-four episodes of tachycardia in seven patients were treated directly by shocks because of short tachycardia cycle length; 88% of all detected tachycardias were treated without the need for shocks. Four patients died from cardiorespiratory failure and one patient died suddenly without any detected tachyarrhythmia.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				Committee Members, G. Gregoratos, J. Abrams, A. E. Epstein, R. A. Freedman, D. L. Hayes, M. A. Hlatky, R. E. Kerber, G. V. Naccarelli, M. H. Schoenfeld, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1703 - 1719. [Full Text] [PDF]

				G. Gregoratos, J. Abrams, A. E. Epstein, R. A. Freedman, D. L. Hayes, M. A. Hlatky, R. E. Kerber, G. V. Naccarelli, M. H. Schoenfeld, M. J. Silka, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) Circulation, October 15, 2002; 106(16): 2145 - 2161. [Full Text] [PDF]

				L. B. Mitchell, E. A. Pineda, J. L. Titus, P. M. Bartosch, and D. G. Benditt Sudden death in patients with implantable cardioverter defibrillators: The importance of post-shock electromechanical dissociation J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1323 - 1328. [Abstract] [Full Text] [PDF]

				S. Nisam A Prophylactic ICD? Who are the patients? What is the device? Europace, January 1, 2001; 3(4): 269 - 274. [PDF]

				A. Schaumann, F. v. z. Muhlen, B. Herse, B.-D. Gonska, and H. Kreuzer Empirical Versus Tested Antitachycardia Pacing in Implantable Cardioverter Defibrillators : A Prospective Study Including 200 Patients Circulation, January 13, 1998; 97(1): 66 - 74. [Abstract] [Full Text] [PDF]

				G. J. Fahy, E. B. Sgarbossa, P. J. Tchou, and S. L. Pinski Hospital Readmission in Patients Treated With Tiered-Therapy Implantable Defibrillators Circulation, September 15, 1996; 94(6): 1350 - 1356. [Abstract] [Full Text]

				R. Sheldon, H. Duff, and M. L. Koshman Antiarrhythmic Activity of Quinine in Humans Circulation, November 15, 1995; 92(10): 2944 - 2950. [Abstract] [Full Text]

				S. L. Pinski and G. J. Fahy The Proarrhythmic Potential of Implantable Cardioverter-Defibrillators Circulation, September 15, 1995; 92(6): 1651 - 1664. [Abstract] [Full Text]

				J. J. Goldberger, J. R. Smith, Y.-H. Kim, R. S. Damle, and A. H. Kadish Effect of Increased Drive-train Stimulus Intensity on Dispersion of Ventricular Refractoriness Circulation, August 15, 1995; 92(4): 875 - 880. [Abstract] [Full Text]

				D. P. Zipes and D. Roberts Results of the International Study of the Implantable Pacemaker Cardioverter-Defibrillator : A Comparison of Epicardial and Endocardial Lead Systems Circulation, July 1, 1995; 92(1): 59 - 65. [Abstract] [Full Text]

				M. A. Wood, P. M. Simpson, B. S. Stambler, J. M. Herre, R. C. Bernstein, and K. A. Ellenbogen Long-term Temporal Patterns of Ventricular Tachyarrhythmias Circulation, May 1, 1995; 91(9): 2371 - 2377. [Abstract] [Full Text]

				S. O. Nunain, M. Roelke, T. Trouton, S. Osswald, Y. H. Kim, G. Sosa-Suarez, D. R. Brooks, B. McGovern, M. Guy, D. F. Torchiana, et al. Limitations and Late Complications of Third-Generation Automatic Cardioverter-Defibrillators Circulation, April 15, 1995; 91(8): 2204 - 2213. [Abstract] [Full Text]

				L.-A. M. Beauregard, P. W. Barnard, A. M. Russo, and H. L. Waxman Perceived and Actual Risks of Driving in Patients With Arrhythmia Control Devices Arch Intern Med, March 27, 1995; 155(6): 609 - 613. [Abstract] [PDF]